Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

Completed · Phase 1

Conditions studied: Cardiovascular Disease

In brief

This study is being conducted to evaluate the safety and the length of effect on platelet build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or subject's current aspirin 81 mg of choice in patients who have Type 2 diabetes mellitus and cardiovascular disease or multiple risk factors of developing cardiovascular disease.

Key facts

Study ID

NCT02370680

Run by

New Haven Pharmaceuticals, Inc.

People needed

41

Starts

2015-02-01

Expected to finish

2015-07-01

Last updated by the study team

2015-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or non-lactating, non-pregnant female subjects
• A history of Type 2 Diabetes and with history of at least one of the following: Coronary Artery Disease, Peripheral Vascular Disease, or Ischemic Stroke, along with at least 2 CVD risk factors (obese, smoker, ≥ 55 years of age, prior thrombotic event)

You may not qualify if…

• Sensitivity to aspirin or any NSAID (nonsteroidal antiinflammatory drug),
• Evidence of uncontrolled or unstable cardio- or cerebrovascular disorder,
• Presence of uncontrolled or chronic medical illness, GI disorder or surgery leading to impaired drug absorption, clinically significant abnormal baseline ECG, history of hepatitis, malignancy within the past five years, or HIV, history of alcohol or drug abuse.

Where it is running

• Platelet and Thrombosis Research, LLC — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.